- Home
- CHRS vs ARL Comparison
CHRS vs ARL Comparison
Compare CHRS & ARL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHRS | ARL |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.5M | 246.8M |
| IPO Year | 2014 | 1999 |
Fundamental Metrics
Financial Performance| Metric | CHRS | ARL |
|---|---|---|
| Price | $1.60 | $15.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.51 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 2.1K |
| Earning Date | 03-09-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 472.00 | 206.59 |
| EPS | ★ 1.43 | 0.97 |
| Revenue | N/A | ★ $50,014,000.00 |
| Revenue This Year | $73.08 | N/A |
| Revenue Next Year | $30.94 | N/A |
| P/E Ratio | ★ $1.14 | $15.75 |
| Revenue Growth | N/A | ★ 5.70 |
| 52 Week Low | $0.72 | $9.43 |
| 52 Week High | $2.62 | $20.00 |
Technical Indicators
Market Signals| Indicator | CHRS | ARL |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 40.18 |
| Support Level | $1.55 | $15.17 |
| Resistance Level | $1.75 | $15.60 |
| Average True Range (ATR) | 0.11 | 0.65 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 20.99 | 31.86 |
Price Performance
Historical ComparisonAbout CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About ARL American Realty Investors Inc.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments: the acquisition, development, ownership and management of multifamily properties (Residential Segment) and the acquisition, ownership and management of commercial real estate properties (Commercial Segment). Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.